Pacira BioSciences, Inc.
PCRXHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Pacira BioSciences, Inc. (PCRX) is listed under Drug Manufacturers - Specialty & Generic. The $1.01B market capitalization puts PCRX squarely in small-cap range for its industry. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve.
Market Cap
$1.01B
Beta
0.27
P/E (TTM)
197.00
P/E (Fwd)
7.02
EPS (TTM)
$0.13
EPS (Fwd)
$3.65
ROE
0.7%
ROA
1.4%
Cash
$202.2M
Total Debt
$411.2M
Free CF
$98.6M
52W Change
18.6%
Annual Financials
Cash vs Debt
Pacira BioSciences, Inc. carries $411.2M in total debt against $202.2M in cash reserves — debt is roughly 2.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $98.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 0.7%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.4% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $666.8M (2022) to $726.4M (2025).
The relatively low beta of 0.27 suggests PCRX is a less volatile holding compared to the broader index. At over 50x earnings, PCRX carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Pacira BioSciences, Inc.'s trajectory.